Janssen studies show cardiovascular benefits of Invokana

Janssen has announced new clinical trial findings that demonstrate the cardiovascular health benefits of its diabetes therapy Invokana.

The company has reported results from the landmark CANVAS programme, showing that Invokana significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke versus placebo in patients with type 2 diabetes at risk of or with a history of cardiovascular disease.

It was also shown that Janssen's drug was associated with a reduced risk for hospitalisation for heart failure and demonstrated potential renal protective effects in the integrated analysis of the CANVAS and CANVAS-R trials.

CANVAS represented the longest, largest and broadest completed cardiovascular outcomes programme of any sodium glucose cotransporter-2 inhibitor, with more than 10,000 patients involved overall.

Dr James List, global therapeutic head of cardiovascular and metabolism at Janssen, said: "With the CANVAS programme results, we are excited to show the positive benefit-risk profile for cardiovascular and renal endpoints."

The drug is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, and has been prescribed for more than 14 million patients in the US alone.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.